Adjunctive Low-Dose Acetylsalicylic Acid in Bipolar Disorder: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase II Trial (ASPIRIN BD)
Journal of Clinical Medicine · 27.10.2026 · 15 (21) · 8349
DOI: 10.3390/jcm15218349 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 27.10.2026. Verfasst von Monika Dominiak und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Institute of Psychiatry and Neurology, 9 Sobieskiego Street, 02-957 Warsaw, Poland. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Agency.
Abstract (Originalsprache)
Background/Objectives: Bipolar depression remains difficult to treat. We evaluated the short-term antidepressant efficacy of adjunctive low-dose acetylsalicylic acid (ASA; 150 mg/day) over 2 months and its longer-term effect on relapse prevention over 12 months.
Methods
ASPIRIN BD (EudraCT 2021-006635-25) was a multicentre, randomised, double-blind, placebo-controlled phase II trial at four Polish centres. Adults aged 18–60 years with a current bipolar depressive episode were randomised 1:1 to ASA or placebo for 12 months. The primary endpoint was the change in HAMD-17 score after 2 months, while the longer-term effect of ASA on relapse or clinical worsening was assessed over 12 months.
Results
One hundred participants were randomised (50 per group). At month 2, ASA reduced HAMD-17 scores versus placebo (adjusted difference −4.24; 95% CI −7.20 to −1.28; p = 0.005; d = −0.51). Relapse or clinical worsening was less frequent with ASA (p = 0.026; NNT = 5). Depressive and bipolar remission rates were higher with ASA at month 6 (both p ≤ 0.003). Safety outcomes and adherence were comparable between groups.
Conclusions
Adjunctive ASA 150 mg/day improved short-term depressive symptoms and reduced relapse or clinical worsening during a 12-month treatment period, with no clear safety signal. These findings warrant phase III confirmation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology, Institute of Psychiatry and Neurology, 9 Sobieskiego Street, 02-957 Warsaw, Poland.
- Department of Psychiatry, Collegium Medicum, Cardinal Stefan Wyszyński University, 01-938 Warsaw, Poland.
- Department of Pharmacology and Third Department of Psychiatry, Institute of Psychiatry and Neurology, 02-957 Warsaw, Poland.
- Holimedyk Mental Health Institute, 42-200 Częstochowa, Poland.
- Regional Mental Health Hospital, 86-100 Świecie, Poland.
ORCID-Profile: Monika Dominiak, Anna Z Antosik, Adam Gędek, Michał Dermanowski, Paweł Mierzejewski
Förderung
- Medical Research Agency
Zitieren
APA
Dominiak, M., Antosik, A. Z., Gędek, A., Krawczyk-Syguda, A., Biedrzycki, S., Kuczyńska, J., Dermanowski, M., & Mierzejewski, P. (2026). Adjunctive Low-Dose Acetylsalicylic Acid in Bipolar Disorder: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase II Trial (ASPIRIN BD). Journal of Clinical Medicine, 15(21), 8349. https://doi.org/10.3390/jcm15218349
Vancouver
Dominiak M, Antosik AZ, Gędek A, Krawczyk-Syguda A, Biedrzycki S, Kuczyńska J, et al. Adjunctive Low-Dose Acetylsalicylic Acid in Bipolar Disorder: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase II Trial (ASPIRIN BD). Journal of Clinical Medicine. 2026;15(21):8349. doi:10.3390/jcm15218349
BibTeX
@article{Dominiak2026,
author = {Dominiak, Monika and Antosik, Anna Z and Gędek, Adam and Krawczyk-Syguda, Anna and Biedrzycki, Sławomir and Kuczyńska, Julita and Dermanowski, Michał and Mierzejewski, Paweł},
title = {Adjunctive Low-Dose Acetylsalicylic Acid in Bipolar Disorder: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase II Trial (ASPIRIN BD)},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {21},
pages = {8349},
doi = {10.3390/jcm15218349}
}
EUVIMED